Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
03:55am, Wednesday, 25'th Feb 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain...
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
02:00am, Tuesday, 10'th Feb 2026
Tiziana Life Sciences (NASDAQ: TLSA - Get Free Report) and Tectonic Therapeutic (NASDAQ: TECX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast
Tiziana Life Sciences publishes positive study on intranasal MS therapy
11:38am, Tuesday, 20'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive multiple sclerosis (SPMS) has been published in the
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
11:15am, Tuesday, 20'th Jan 2026
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering
03:02pm, Friday, 16'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership and existing shareholders, as the biotechnology company moves to a
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
02:45pm, Friday, 16'th Jan 2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Tiziana Life Sciences unveils registered direct offering of up to $17.6M
09:00am, Friday, 16'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately $17.6 million in gross proceeds, including potential proceeds fr
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
07:00am, Friday, 16'th Jan 2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum
03:15am, Friday, 09'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO, Ivor Elrifi, will present at the 9th Annual Neuroscience Innovation Forum on January 11 during J.P....
Oil market surplus predicted to widen through early 2026
07:38am, Monday, 05'th Jan 2026
The oil market surplus that arrived in the second half of 2025 is predicted, by analysts at Morgan Stanley, to widen in early 2026, pushing the Brent...
Saks Global CEO Marc Metrick steps down as retailer reportedly nears bankruptcy
07:08am, Friday, 02'nd Jan 2026
Saks Global CEO Marc Metrick, a 30-year veteran of the luxury retailer, has stepped down to pursue “new opportunities,” the company announced Friday....
Nasdaq, S&P 500 move lower as 2026 trading gets underway
07:04am, Friday, 02'nd Jan 2026
12:04pm: Wall Street wobbles US stocks edged lower in the early afternoon on Friday, led by a 0.4% drop in the Nasdaq. The S&P 500 was down 0.2% and the Dow...
Nasdaq ends Monday in the red in subdued post-holiday session
11:22am, Monday, 29'th Dec 2025
4:20pm: Wall Street cools after holiday rally Stocks closed in the red on Monday, taking a small step back after wrapping up a shortened Christmas trading...
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA
09:11am, Monday, 29'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the US Food and Drug Administration (FDA), reporting no drug-rela
